We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| York Pharma | LSE:YRK | London | Ordinary Share | GB00B00QHC86 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.25 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMYRK
RNS Number : 1983P
York Pharma plc
20 March 2009
20 March 2009
York Pharma plc
(YRK.L) ("York" or the "Company")
Market Update
In January 2009, York announced that its newly appointed management team were
investigating options to address the Company's short term funding needs and that
the Company's results for the financial year ended 30 September 2008 ('the
Results') would be released today.
On 2 March 2009, the Board confirmed that the Company had made an approach to a
potential offeror which may or may not lead to an offer being made for the
Company. The Board remains in discussions with this and another potential
offeror. These discussions also include provision of the necessary short term
funding facilities to allow the Company to continue trading through the period
needed to complete any formal offer for the Company under the Takeover Code.
The Board remains hopeful that a positive outcome to these discussions can be
achieved.
Publication of the Results will now take place after the Company has secured its
short term funding needs and the Board will provide a further update shortly.
For more information please contact:
+-----------------------------------------+------------------------------+
| York Pharma plc | Tel: +44 (0) 870 066 4453 |
| Richard Anderson, Chief Executive | |
| Officer | |
+-----------------------------------------+------------------------------+
| Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 |
| Hugh Field / Adam Cowen | |
+-----------------------------------------+------------------------------+
| FinnCap | Tel: +44 (0) 207 600 1658 |
| Geoff Nash | |
+-----------------------------------------+------------------------------+
| Financial Dynamics | Tel: +44 (0) 207 831 3113 |
| Ben Brewerton / Emma Thompson | |
+-----------------------------------------+------------------------------+
Collins Stewart Europe Limited ("Collins Stewart") which is regulated in the
United Kingdom by The Financial Services Authority is acting for the Company in
relation to the matters described in this announcement and is not advising any
other person, and accordingly will not be responsible to anyone other than the
Company for providing the protections afforded to customers of Collins Stewart
or for providing advice in relation to the matters described in this
announcement.
About York Pharma plc
York Pharma plc is a pharmaceutical group, established in 2003, which develops,
markets and supplies branded dermatological products to pharmaceutical
wholesalers, hospitals and general practitioners within the field of
dermatology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
OFDPUUAPWUPBUBU
1 Year York Pharma Chart |
1 Month York Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
